ESR1 and neoplasm: When combined with abemaciclib (a CDK4/6 inhibitor), alpelisib (a PI3K inhibitor), or everolimus (a mTOR inhibitor), imlunestrant demonstrates enhanced anti-tumor efficacy, including against brain metastases, irrespective of ESR1-mutation status (29).